Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Memorial Sloan Kettering Cancer Center · South Texas Accelerated Research Therapeutics · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
480
total citations
- FWCI
- 62.89
- Percentile
- 100%
- References
- 27
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Lenvatinib
- Medicine
- Pembrolizumab
- Internal medicine
- Oncology
- Endometrial cancer
- Clinical endpoint
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.